Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-89P, or RNA, U6 small nuclear 89, pseudogene, is annotated as a **pseudogene** of U6 small nuclear RNA (snRNA), which means it is a genomic DNA sequence similar to known genes that is generally not transcribed into functional RNA or protein[1][4][5]. The functional (non-pseudogene) U6 snRNA is a critical component of the spliceosome, the molecular machine responsible for the removal of introns from pre-messenger RNA in eukaryotic cells[2][3]. However, pseudogenes like RNU6-89P do not encode an active RNA product and thus do not carry out any known biological function or regulatory role and are not considered therapeutic targets[1][5]. There are no drugs, disease associations, or biomarker roles known for this specific pseudogene. Its presence in the genome reflects the high number of U6-related pseudogenes in vertebrates, likely arising through gene duplication or retrotransposition events, but it is not a target for therapeutic modulation or biomedical research[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 89, pseudogene (RNU6-89P).